 |
 Video: What is a Stock Split?
|
|
|
| Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Co. is building a multi-modality product pipeline. Co.'s primary activities include developing T cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license arrangements, enabling manufacturing activities in support of its product candidate development efforts, organizing and staffing Co., establishing its intellectual property portfolio, regulatory submissions and other preparations to initiate clinical trials, raising capital and providing general and administrative support for these activities. According to our Lyell Immunopharma stock split history records, Lyell Immunopharma has had 0 splits. | |
|
Lyell Immunopharma (LYEL) has 0 splits in our Lyell Immunopharma stock split history database.
Looking at the Lyell Immunopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lyell Immunopharma shares, starting with a $10,000 purchase of LYEL, presented on a split-history-adjusted basis factoring in the complete Lyell Immunopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/18/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$16.20 |
|
| End price/share: |
$2.17 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-86.60% |
|
| Average Annual Total Return: |
-50.52% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,339.13 |
|
| Years: |
2.86 |
|
|
|
|
|
